NexPlasmaGen Incorporée

5 records totalling $619,010.00 CAD, from official Government of Canada open data.

Embed this chart

By department

National Research Council Canada $569,010 4 records
Canada Economic Development for Quebec Regions $50,000 1 record

Records

NexPlasmaGen Incorporée $202,810.00
National Research Council Canada | Conseil national de recherches Canada
Industrial Research Assistance Program – Contributions to Firms
FY 2021-2022
Canada

This project will allow to prepare a unique high precision cold plasma device prototype for breast cancer treatment so it can be authorized by Health Canada for an investigational testing (first-in-hu...

NexPlasmaGen Incorporée $197,000.00
National Research Council Canada | Conseil national de recherches Canada
Industrial Research Assistance Program
FY 2025-2026
Canada

The project involves the conceptual design of the pre-production applicator and its in vitro testing for breast cancer, followed by the conceptual design of the pre-production control unit.

NexPlasmaGen Incorporée $119,200.00
National Research Council Canada | Conseil national de recherches Canada
Industrial Research Assistance Program – Contributions to Firms
FY 2019-2020
Canada

This project enhances the development of a unique high precision cold plasma device as a adjuvant for breast cancer radiotherapy. More particularly, the detailed design, fabrication and commissioning...

Nexplasmagen incorporée $50,000.00
Canada Economic Development for Quebec Regions | Développement économique Canada pour les régions du Québec
REGI - Commercialization and exportation
FY 2026-2027
Canada

Marketing strategy: The project aims to increase the sales of a company specializing in designing medical device technology.

NexPlasmaGen Incorporée $50,000.00
National Research Council Canada | Conseil national de recherches Canada
Industrial Research Assistance Program – Contributions to Firms
FY 2018-2019
Canada

This project assesses a unique device as a potential adjuvant for breast cancer radiotherapy to enhance the selective kill of breast cancer cells in order to reduce cancer recurrence.